References
- Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, Vos T. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109:1320–33.
- Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years. Risk factors and lives saved. Drug Alcohol Depend. 2009;105:9–15. doi:https://doi.org/10.1016/j.drugalcdep.2009.05.021.
- Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87:82–88. doi:https://doi.org/10.1016/j.biopsych.2019.06.020.
- Drew L. Opioids by the numbers. Nature. 2019;573:S2–S3. doi:https://doi.org/10.1038/d41586-019-02682-6.
- Crotty K, Freedman K, Kampman K. Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder. J Addict Med. 2020;14:99–112. doi:https://doi.org/10.1097/ADM.0000000000000635.
- Jordan CJ, Cao J, Newman AH, Xi ZX. Progress in agonist therapy for substance use disorders: lessons learned from methadone and buprenorphine. Neuropsychopharmacology. 2019;158:107609.
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;CD002207. doi:https://doi.org/10.1002/14651858.CD002207.
- Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375:1596–97. doi:https://doi.org/10.1056/NEJMra1604339.
- Havnes I, Bukten A, Gossop M, Waal H, Stangeland P, Clausen T. Reductions in convictions for violent crime during opioid maintenance treatment: a longitudinal national cohort study. Drug Alcohol Depend. 2012;124:307–10. doi:https://doi.org/10.1016/j.drugalcdep.2012.02.005.
- Hser Y-I, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109:8–18.
- Hser Y-I, Huang D, Saxon AJ, Woody G, Moskowitz AL, Matthews AG, Ling W. Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+ naloxone and methadone. J Addict Med. 2017;11:63–69.
- Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK general practice research database. BMJ. 2010;341:c5475. doi:https://doi.org/10.1136/bmj.c5475.
- Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitition therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015;2:901–08. doi:https://doi.org/10.1016/S2215-0366(15)00366-1.
- Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessling L, Ferri M, Pastor-Barriuso R, Vecchi S. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
- Amato L, Minozzi S, Davoli M. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;10:CD004147.
- Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen H-U, et al. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res. 2017;23:97–105.
- Kelty EA, Cumming CN, Troeung L, Hulse GK. Buprenorphine alone or with naloxone: which is safer? J Psychopharmacol. 2018;32:344–52. doi:https://doi.org/10.1177/0269881118756015.
- Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;984:441–52. doi:https://doi.org/10.1046/j.1360-0443.2003.00335.x.
- O’Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. Plos One. 2020;15:e0232086. doi:https://doi.org/10.1371/journal.pone.0232086.
- Soyka M. Novel long-acting buprenorphine medications for opioid dependence: current update. Pharmacopsychiatry. 2021;54:18–22. doi:https://doi.org/10.1055/a-1298-4508.
- Strain EC, Preston KL, Liebson IA, Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther. 1995;272:428–38.
- Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine in methadone-maintained subjects. Psychopharmacology. 1995;119:268–76.
- Lintzeris N, Monds LA, Rivas C, Leung S, Dunlop A, Newcombe D, Walters C, et al. Transferring patients from methadone to buprenorphine: the feasability and evaluation of practice guidelines. J Addict Med. 2018;12:234–40.
- American society of addiction medicine: national practice guideline for the treatment of opioid use disorder. 2020. Focused Update. (assessed 28.October.2020)
- Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, et al. Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomised clinical trial. JAMA Psychiatry. 2017;74:894–902.
- Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual burpenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178:764–73.
- Haight BR, Learned SM, Laffont CM, Fudala J, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C, et al. RB-US-13-0001 study investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393:778–90.
- Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304:1576–83. doi:https://doi.org/10.1001/jama.2010.1427.
- Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108:2141–49.
- Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, Bailey GL, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA. 2016;316:282–90.
- Bukten A, Skurtveit S, Strangeland P, Gossop M, Willersrud AB, Waal H, Havnes I, Clausen T. Criminal convictions among heroin users reductions in convictions for violent crime during opioid maintenance during a 3-year period prior to opioid maintenance treatment: a longitudinal national cohort study. J Subst Abuse Treat. 2011;41:407–14. doi:https://doi.org/10.1016/j.jsat.2011.06.006.
- Soyka M, Träder A, Klotsche J, Haberthür A, Bühringer G, Rehm J, Wittchen H-U. Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. J Forensic Sci. 2012;57:1524–30. doi:https://doi.org/10.1111/j.1556-4029.2012.02234.x.
- Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018;113:656–67.
- Sun H-M, Li X-Y, Chow EPF, Li T, Xian Y, Le Y-H, Tian T, Zhuang X, Zhang L. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drugs users in China: a systematic review and meta-analysis. BMJ Open. 2015;5:e005997. doi:https://doi.org/10.1136/bmjopen-2014-005997.
- Vorma H, Sokero P, Aaltonen M, Turtiainen S, Hughes LA, Savolainen J. Participation in opioid substitution treatment reduces the rate of criminal convictions: evidence from a community study. Addict Behav. 2013;38:2313–16. doi:https://doi.org/10.1016/j.addbeh.2013.03.009.
- Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Sbuse Treat. 2019;99:32–43. doi:https://doi.org/10.1016/j.jsat.2018.12.003.
- Groß G, Conroy S, Leobardi C, Merouch F, Antolin JM, Somaini L. Reducing opioid dependence therary risk in the prison system and the use of extended-release buprenorphine as an additional treatment: a consensus statement. Heroin Addict Relat Clin Probl. 2021. (in press).
- Opitz-Welke A, Lehmann M, Seidel P, Konrad N. Medicine in the penal system. Dtsch Arztebl Int. 2018;115:808–14.
- Bernuth KV, Seidel P, Krebs J, Lehmann M, Neumann KN, Opitz-Welke A. Prevalence of opioid dependence and opioid agonist treatment in the Berlin custodial setting: a cross-sectional study. Front Psychiatry. 2020;11:794. doi:https://doi.org/10.3389/fpsyt.2020.00794.
- Moe J, O’Sullivan F, Hohl CM, Doyle-Waters MM, Ronsley C, Cho R, Liu Q, Azar P. Short communication: systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021;114:106740. doi:https://doi.org/10.1016/j.addbeh.2020.106740.
- Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict;2020 Dec 20. doi:https://doi.org/10.1111/ajad.13135
- Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253–25. doi:https://doi.org/10.1080/02791072.2003.10400007.
- Groß G. Entwicklung der Substitutionsbehandlung im bayerischen Strafvollzug am Beispiel der Justizvollzugsanstalt Straubing. Suchtmed. 2021;23:74–80.
- Völlm B, Cerci D. Substitutionsbehandling im Maßregelvollzug. Suchtmed. 2021;23:90–98.
- Wild CT, Hammal F, Hancock M, Bartlett NT, Gladwin KK, Adams D, Loverock A, Hodgins DC. Forty-Eight Years of research on psychosocial interventions in the treatment of opioid use disorder: a scoping review. Drug Alcohol Depend. 2021;218:108434. doi:https://doi.org/10.1016/j.drugalcdep.2020.108434.
- Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes in incarcerated persons: a systematic review. Plos Med. 2019;16:e1003002. doi:https://doi.org/10.1371/journal.pmed.1003002.